microRNA: Diagnostic perspective

Frontiers in Medicine

Volumn 2, Issue AUG, 2015, Pages

  Faruq, Omar ^a   Vecchione, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biomarkers; Diagnosis; Micro RNA

Indexed keywords

EID: 84964570956     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00051     Document Type: Review

References (100)

1. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx (2004) 1(2):182-8. doi: 10.1602/neurorx.1.2.182
2. Dbouk HA, Tawil A, Nasr F, Kandakarjian L, Abou-Merhi R. Significance of CEA and VEGF as diagnostic markers of colorectal cancer in Lebanese patients. Open Clin Cancer J (2007) 1:1. doi:10.2174/1874189400701010001
3. Stenman U-H, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol (1999) 9(2):83-93. doi:10.1006/scbi.1998.0086
4. Felekkis K, Touvana E, Stefanou CH, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia (2010) 14(4):236
5. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol (2009) 11(3):228-34. doi:10.1038/ncb0309-228
6. Landi D, Gemignani F, Landi S. Role of variations within microRNA-binding sites in cancer. Mutagenesis (2012) 27(2):205-10. doi:10.1093/mutage/ger055
7. Paranjape T, Slack F, Weidhaas J. microRNAs: tools for cancer diagnostics. Gut (2009) 58(11):1546-54. doi:10.1136/gut.2009.179531
8. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2009) 19(1):92-105. doi:10.1101/gr.082701.108
9. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. microRNA maturation: stepwise processing and subcellular localization. EMBO J (2002) 21(17):4663-70. doi:10.1093/emboj/cdf476
10. Zeng Y, Yi R, Cullen BR. microRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A (2003) 100(17):9779-84. doi:10.1073/pnas.1630797100
11. Ambros V, Lee RC. Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning. In: Gott JM, Clifton NJ, editors. RNA Interference, Editing, and Modification. Springer (2004). p. 131-58
12. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science (2004) 303(5654):95-8. doi:10.1126/science.1090599
13. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17(24):3011-6. doi:10.1101/gad.1158803
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 105(30):10513-8. doi:10.1073/pnas.0804549105
15. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 18(10):997-1006. doi:10.1038/cr.2008.282
16. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 108(12):5003-8. doi:10.1073/pnas.1019055108
17. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. microRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 13(4):423-33. doi:10.1038/ncb2210
18. Berezikov E, Plasterk RH. Camels and zebrafish, viruses and cancer: a microRNA update. Hum Mol Genet (2005) 14(Suppl 2):R183-90. doi:10.1093/hmg/ddi271
19. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell (2005) 122(1):6-7. doi:10.1016/j.cell.2005.06.036
20. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, et al. microRNAs regulate brain morphogenesis in zebrafish. Science (2005) 308(5723):833-8. doi:10.1126/science.1109020
21. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 141(5):672-5. doi:10.1111/j.1365-2141.2008.07077.x
22. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med (2013) 11(1):31. doi:10.1186/1479-5876-11-31
23. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 122(11):1891-9. doi:10.1182/blood-2013-01-478222
24. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol (2011) 6(3):482-8. doi:10.1097/JTO.0b013e318208c785
25. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol (2011) 4(6):575
26. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 128(3):608-16. doi:10.1002/ijc.25376
27. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 106(4):768-74. doi:10.1038/bjc.2011.595
28. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. microRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PLoS One (2013) 8(10):e76994. doi:10.1371/journal.pone.0076994
29. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. microRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA (2014) 311(4):392-404. doi:10.1001/jama.2013.284664
30. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol (2011) 45(4):355-60. doi:10.1097/MCG.0b013e3181f18ac2
31. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 2(2):e000825. doi:10.1136/bmjopen-2012-000825
32. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol (2012) 56(6):1371-83. doi:10.1016/j.jhep.2011.11.026
33. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer (2012) 3:19. doi:10.7150/jca.3.19
34. Ayaz L, Görür A, Yaroglu HY, Ozcan C, Tamer L. Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol (2013) 139(9):1499-506. doi:10.1007/s00432-013-1469-2
35. Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark (2012) 12(4):199-204. doi:10.3233/CBM-130308
36. Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One (2014) 9(4):e87451. doi:10.1371/journal.pone.0087451
37. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 259(4):735-43. doi:10.1097/SLA.0b013e3182a6909d
38. Tsujiura M, Komatsu S, Ichikawa D, Shiozaki A, Konishi H, Takeshita H, et al. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer (2014) 18:1-9. doi:10.1007/s10120-014-0363-1
39. Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep (2014) 31(4):1863-70. doi:10.3892/or.2014.3004
40. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One (2013) 8(11):e77853. doi:10.1371/journal.pone.0077853
41. Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Morimura R, Nagata H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer (2011) 105(1):104-11. doi:10.1038/bjc.2011.198
42. Kishimoto T, Eguchi H, Nagano H, Kobayashi S, Akita H, Hama N, et al. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer. Cancer Sci (2013) 104(12):1626-31. doi:10.1111/cas.12300
43. Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol (2012) 138(4):671-4. doi:10.1007/s00432-012-1147-9
44. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2012) 97(6):2084-92. doi:10.1210/jc.2011-3059
45. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer (2013) 132(1):116-27. doi:10.1002/ijc.27657
46. Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J (2013) 7(1-2):28. doi:10.5489/cuaj.11115
47. Chen W, Wang H, Chen H, Liu S, Lu H, Kong D, et al. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. Eur J Haematol (2014) 92(5):407-12. doi:10.1111/ejh.12263
48. Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J, et al. microRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2011) 108(16):6573-8. doi:10.1073/pnas.1019557108
49. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest (2011) 91(4):579-87. doi:10.1038/labinvest.2010.194
50. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer (2012) 130(7):1620-8. doi:10.1002/ijc.26177
51. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol (1987) 138(5):1181-4
52. Schröder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol (2009) 19(3):227-31. doi:10.1097/MOU.0b013e328329a2d0
53. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 77(5):1265.e9-16. doi:10.1016/j.urology.2011.01.020
54. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One (2014) 9(4):e92921. doi:10.1371/journal.pone.0092921
55. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer (2014) 110(9):2291-9. doi:10.1038/bjc.2014.119
56. Zhao A, Li G, Péoc'h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol (2013) 94(1):115-20. doi:10.1016/j.yexmp.2012.10.005
57. Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OB, Heegaard NH. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls. Pancreas (2013) 42(7):1107-13. doi:10.1097/MPA.0b013e318296bb34
58. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive-gene expression in paraffin-embedded tissue. J Pathol (2001) 195(1):66-71. doi:10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F
59. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res (1999) 27(22):4436-43. doi:10.1093/nar/27.22.4436
60. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. microRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 47(4):1223-32. doi:10.1002/hep.22158
61. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA (2007) 13(10):1668-74. doi:10.1261/rna.642907
62. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol (2007) 7(1):36. doi:10.1186/1472-6750-7-36
63. McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, et al. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One (2014) 9(1):e87032. doi:10.1371/journal.pone.0087032
64. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. microRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 11(3):R27. doi:10.1186/bcr2257
65. de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics (2013) 14(1):643. doi:10.1186/1471-2164-14-643
66. van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res (2015) 17(1):21. doi:10.1186/s13058-015-0526-y
67. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 59(5):721-30. doi:10.1016/j.eururo.2011.01.004
68. Lee JH, Voortman J, Dingemans AM, Voeller DM, Pham T, Wang Y, et al. microRNA expression and clinical outcome of small cell lung cancer. PLoS One (2011) 6(6):e21300. doi:10.1371/journal.pone.0021300
69. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol (2009) 27(12):2030-7. doi:10.1200/JCO.2008.19.4134
70. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, et al. Microrna expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer (2007) 121(5):1156-61. doi:10.1002/ijc.22800
71. Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol (2015) 16(1):18. doi:10.1186/s13059-014-0568-y
72. Laginestra MA, Piccaluga PP, Fuligni F, Rossi M, Agostinelli C, Righi S, et al. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J (2014) 4(11):259. doi:10.1038/bcj.2014.78
73. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, et al. microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood (2013) 122(12):2083-92. doi:10.1182/blood-2012-08-447375
74. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American heart association. Circulation (2010) 121(7):948. doi:10.1161/CIRCULATIONAHA.109.192666
75. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al. microRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 8(10):R214. doi:10.1186/gb-2007-8-10-r214
76. Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev (2014) 40(5):595-604. doi:10.1016/j.ctrv.2013.11.002
77. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn (2012) 14(5):510-7. doi:10.1016/j.jmoldx.2012.03.004
78. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and Overview of the Classification of the Lymphoid Neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). p. 157-66
79. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation (2003) 107(3):499-511. doi:10.1161/01.CIR.0000052939.59093.45
80. Saenger AK, Jaffe AS. Requiem for a heavyweight the demise of creatine kinase-MB. Circulation (2008) 118(21):2200-6. doi:10.1161/CIRCULATIONAHA.108.773218
81. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature (2011) 469(7330):336-42. doi:10.1038/nature09783
82. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res (2010) 106(6):1035-9. doi:10.1161/CIRCRESAHA.110.218297
83. Fan KL, Zhang HF, Shen J, Zhang Q, Li XL. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J (2013) 65(1):12-6. doi:10.1016/j.ihj.2012.12.022
84. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J (2010) 31(22):2765-73. doi:10.1093/eurheartj/ehq167
85. Shi KH, Tao H, Yang JJ, Wu JX, Xu SS, Zhan HY. Role of microRNAs in atrial fibrillation: new insights and perspectives. Cell Signal (2013) 25(11):2079-84. doi:10.1016/j.cellsig.2013.06.009
86. Jaguszewski M, Osipova J, Ghadri JR, Napp LC, Widera C, Franke J, et al. A signature of circulating microRNAs differentiates Takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J (2014) 35(15):999-1006. doi:10.1093/eurheartj/eht392
87. Osipova J, Fischer DC, Dangwal S, Volkmann I, Widera C, Schwarz K, et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metab (2014) 99(9):E1661-5. doi:10.1210/jc.2013-3868
88. Peng H, Zhong M, Zhao W, Wang C, Zhang J, Liu X, et al. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS One (2013) 8(12):e82607. doi:10.1371/journal.pone.0082607
89. Duan X, Zhan Q, Song B, Zeng S, Zhou J, Long Y, et al. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J Diabetes Complications (2014) 28(5):705-10. doi:10.1016/j.jdiacomp.2014.04.012
90. Luo M, Li R, Deng X, Ren M, Chen N, Zeng M, et al. Platelet-derived miR-103b as a novel biomarker for early diagnosis of type 2 diabetes. Acta Diabetol (2015)
91. Monteleone K, Selvaggi C, Cacciotti G, Falasca F, Mezzaroma I, D'Ettorre G, et al. microRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients. BMC Infect Dis (2015) 15(1):51. doi:10.1186/s12879-015-0768-4
92. Munshi SU, Panda H, Holla P, Rewari BB, Jameel S. microRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. PLoS One (2014) 9(5):e95920. doi:10.1371/journal.pone.0095920
93. Sekar D, Hairul Islam VI, Thirugnanasambantham K, Saravanan S. Relevance of miR-21 in HIV and non-HIV-related lymphomas. Tumor Biol (2014) 35(9):8387-93. doi:10.1007/s13277-014-2068-9
94. Jansen C, Reiberger T, Huang J, Eischeid H, Schierwagen R, Mandorfer M, et al. Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS One (2015) 10(2):e0116768. doi:10.1371/journal.pone.0116768
95. Hanson EK, Lubenow H, Ballantyne J. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal Biochem (2009) 387(2):303-14. doi:10.1016/j.ab.2009.01.037
96. de Planell-Saguer M, Rodicio MC. Detection methods for microRNAs in clinic practice. Clin Biochem (2013) 46(10):869-78. doi:10.1016/j.clinbiochem.2013.02.017
97. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS, et al. Real-time PCR quantification of precursor and mature microRNA. Methods (2008) 44(1):31-8. doi:10.1016/j.ymeth.2007.09.006
98. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 6(9):e24145. doi:10.1371/journal.pone.0024145
99. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci (2012) 57(4):897-904. doi:10.1007/s10620-011-1981-7
100. Sanders I, Holdenrieder S, Walgenbach-Brünagel G, von Ruecker A, Kristiansen G, Müller SC, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol (2012) 19(11):1017-25. doi:10.1111/j.1442-2042.2012.03082.x